Hyun J Kim

Emailkimxx015umnedu

Research activity per year

If you made any changes in Pure these will be visible here soon.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

Fingerprint

The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

1 Similar Profiles

8 Active
31 Finished

A Randomized, Doubleblind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis
Kim, H. J.
UNITED THERAPEUTICS CORPORATION
4/15/23 → 4/15/25
Project: Research project
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)
Kim, H. J.
BOEHRINGER-INGELHEIM PHARMACEUTICALS
10/1/22 → 9/30/24
Project: Research project
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
Kim, H. J.
BOEHRINGER-INGELHEIM PHARMACEUTICALS
10/1/22 → 9/30/24
Project: Research project
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)
Kim, H. J.
FIBROGEN, INC
9/14/22 → 9/1/25
Project: Research project
A multi-center, real-world exploratory cohort study to evaluate cough frequency, severity, and impact on quality of life in patients with non-idiopathic pulmonary fibrosis interstitial lung disease
Kim, H. J.
BOEHRINGER-INGELHEIM PHARMACEUTICALS
3/15/22 → 3/15/25
Project: Research project

42 Article
3 Review article
2 Letter
1 Chapter

Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis
IPF-PRO Registry investigators & Kim, H. J., Apr 2023, In: Clinical Therapeutics. 45, 4, p. 306-315 10 p.
Research output: Contribution to journal › Article › peer-review
1 Scopus citations
Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone
Kubbara, A., Amundson, W. H., Herman, A., Lee, A. M., Bishop, J. R. & Kim, H. J., Aug 2023, In: Heliyon. 9, 8, e18573.
Research output: Contribution to journal › Article › peer-review

Open Access
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials
ISABELA 1 and 2 Investigators & Kim, H. J., May 9 2023, In: JAMA. 329, 18, p. 1567-1578 12 p.
Research output: Contribution to journal › Article › peer-review
13 Scopus citations
Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort
Todd, J. L., Neely, M. L., Overton, R., Mulder, H., Roman, J., Lasky, J. A., De Andrade, J. A., Gulati, M., Huang, H., Leonard, T. B., Hesslinger, C., Noth, I., Belperio, J. A., Flaherty, K. R., Palmer, S. M. & Kim, H. J., Feb 1 2022, In: Lung. 200, 1, p. 11-18 8 p.
Research output: Contribution to journal › Article › peer-review

Open Access
2 Scopus citations
Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
the IPF-PRO Registry Investigators, Dec 2022, In: Respiratory research. 23, 1, 3.
Research output: Contribution to journal › Article › peer-review

Open Access

Hyun J Kim

Personal profile

Expertise related to UN Sustainable Development Goals

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

A Randomized, Doubleblind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis

A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)

A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

A multi-center, real-world exploratory cohort study to evaluate cough frequency, severity, and impact on quality of life in patients with non-idiopathic pulmonary fibrosis interstitial lung disease

Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis

Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials

Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort

Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry

Hyun J Kim

Personal profile

Expertise related to UN Sustainable Development Goals

Fingerprint

Collaborations and top research areas from the last five years

Projects

Research output